Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
66 participants
INTERVENTIONAL
2001-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3
NCT00000354
Lofexidine for Inpatient Opiate Detox
NCT00235729
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
NCT00000358
Open-Label, Safety Study of Lofexidine
NCT02363998
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
NCT01863186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lofexidine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Britannia Pharmaceuticals Ltd.
INDUSTRY
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
National Institute on Drug about
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ann Montgomery, R.N.
Role: PRINCIPAL_INVESTIGATOR
National Institute on Drug Abuse (NIDA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Medical Center
Los Angeles, California, United States
Columbia University
New York, New York, United States
Philadelphia Veterans Medical Center
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CSP-1020-1
Identifier Type: -
Identifier Source: org_study_id
NCT00007566
Identifier Type: -
Identifier Source: nct_alias
NCT00024713
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.